<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 327 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page326.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=327">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 327 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 327</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=327"><img src="../thumb/327.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>290 / 2020-04                                                          Endocrine System - 19.1.2
   (S3) TABS, 31/21.2/0588      ren./ hepat.insuffic.in which case insul.is recomm., miconazole   sev.infect./ trauma & shock/ intravasc.admin.of iodinat. contrast
   868906-018: 80 mg, 60, R68,09  treatm., pregn., lactat.    agents, ac./chron.dis.where tiss.hypox. poss. be induc.such as
   Dosage: Indiv. 1 tab.dly. for mild cases. Aveg.dos: 1 tab 2xdly   Side effects: Hypoglycaem.with poss.signs of adrenerg.counter-  card./resp.fail./rec.MI/ pancreatit., hepat.insuffic., ac.alcoh.intox.,
   with meals.                  regulat., GI disturbs., skin reacts. incl. Stev.John.syndr.& TEN, drug   alcohol., safety in pregn.& lactat.not est.
   (S3) DIAGLUCIDE MR           rash with eosinophil. & system.sympts.(DRESS), bld.dyscras., incr.   Sideeffects: Lact.acidos., megaloblast.anaem., hypersens., hypo-
   Indications: Type 2 diabet.with diet.meas./ lifestyle chang.& ex-  hepat.enzym.lev., trans.vis. disturbs., class attribut.effs.of allerg.  glycaem., decr.Vit. B 12 & folic acid absorpt., headache, GI disturbs.,
   erc.when diet.meas./lifestyle & exerc.alone insuffic.  vasculit./ hyponatraem., liv.funct.impairm., hepatit.poss. lead. to   metall.taste, abdom. pain, abnorm.LFT, sev.cholestat.hepatit., skin
   (S3) TABS, 38/21.2/0223, 43/21.2/0960  life-threat. liv.fail.  reacts., weight loss.
   714582-001: 30 mg, 60, R88,22  Warnings and special precautions: Assoc. incr. CV mortal.as   Special precautions: Insul.alone to be used dur. pregn./plann.
   718247-001: 60 mg, 30, R61,90  compar.to diet alone/diet & insulin., monit.concom.anticoags.&   pregn., cross.placenta, distrib. into breast milk, reduc.incid.of lac-
   Dosage: Adults: Dly.dos.30-120 mg/day as sngl.dly.dos. with   dos.adjustm. poss., reduc.dos.poss.necess.in mild to mod.ren. im-  tat.acidos.by assess. assoc.risk fact., discont.& hospitalis. immed.
   breakf. Adjust.accord.to indiv.metabol. respons. Init.30 mg once   pairm., poor nutrit./irreg./miss.meals/condit. favour.hypoglycaem.,   if lact.acidos.susp., monit.ren.funct.bef. init.ther.& reg.thereaft.
   dly.with breakf.             hypoglycaem.risks tog.with sympts./treatm.& predispos.condits.to   esp.elderly/condits.where ren.funct.impair., discont.ther.bef.intra-
   If fast.bld.gluc.lev.not decr.satisfact.incr.dos. progress. to 60 mg,90   be explain., imbal.betw.physic.exerc.& carbohydr. intake, bld.gluc.  vasc. admin. of iodinat.contrast mat.& reinstit.aft.ren. funct. contr.
   mg or 120 mg/day with 1 mnth. interv.betw.increm.except where   contr.poss.affect.by fev./trauma/ infect.or surg.intervent.& insul.ad-  regain., discont.48 hrs.bef.elect. surg./ gen. anaesthes.& re-start
   bld.gluc. has not decr.aft.15 days when an incr.poss.at end of 2   nd  min.poss. necess., second.fail aris.from effic.poss.attenuat. over time   not bef.48 hrs. aft., confirm Type 2 diab.bef.init.ther., pre-pubert.
   wk.of treatm. Max.dly.dos: 120 mg.  due to dis progress/reduc.treatm. respons., consid.adeq.dos.adjust.&   childr.to be monit.as no longt.studies, fast./malnutrit., avoid.al-
   Gliclazide replacem.ther: 80 mg gliclazide = ½ tab.Diaglucide   diet. compliance bef.second.fail.classific., monit.bld. gluc. with con-  coh./alcoh.-cont.meds., more freq.bld.gluc.monit.with concom.
   MR 60 mg.                    com.fluoroquinolones & St John’s Wort, shock/post.anaesth., dis-  glucocortic. / beta-2-agonist/diurets.esp.init., annual Vit. B 12 lev.
   Other sulphonylur.replacem.ther: When tfd. consid. dos.& half-  cont.in event of cholestat. jaund., consid.non-sulphonylur. alternat.   assessm.with contin.ther., concom.sulphonylur., contin.diet with
   life of prev.oral hypoglycaem. If chang.from another oral sulphonylur.  with G6PD defic., when tfd.from another oral hypoglycaem.consid.  reg. carbohydr.distrib.dur.day/energy-restrict.diet in overweight
   with prolong. half-life a therapeut.wind.of a few days poss. necess.   dos.& half-life of prev. agent., ß-block.may mask sympathomimet.  pts., usual lab.tests advis.reg., stabil.in hosp.if concom.insul.ad-
   to avoid addit.eff.& hypoglycaem.risk. Dur. changeover init.30 mg/  warn. signs of hypoglycaem.& inhib.norm.physiolog. respons., do   min., poss.dos. adjustm. with anticoags.
   day incr.increm.accord.to pts metabol.evolut.  not admin.with heredit.galact.intol./ Lapp lact.defic.or gluc.galact.  Drug interactions: Incr.hypoglycaem.risk with concom. meds.
   Other oral antidiabet.combinat: Check control with bld.sugar   malabsorpt.as lactose poss.affects.glycaem.control, safety in pregn.   lower.bld.gluc.conc., reduc.eff. with meds.incr.bld.gluc., incr.lact.
   read.when combin.with alpha glucosid.inhibit./insul. Great.risk of   & lactat.not est., hypoglycaem.can recur. even if init.meas.prove ef-  acidos.risk with ac. alcoh. intoxicat., ACE inhibit.decr.bld.gluc. lev.,
   CV mortal. when combin.with biguan.  fect.theref.seek medic. treatm.  reduc. ren.clear.with cimetidine, hypoglycaem. with sulphonylur.,
   Contraindications: Other sulphonylurea/ sulphonam. hypers-  Drug interactions: Miconazole & phenylbutazone incr.hypogly-  Vit.B 12 malabsorpt. with longt.use.
   ens., type 1 diab., diab. ketoacidos., diab.pre-coma& coma, childr.,   caem.eff., avoid alcohol/meds cont.alcohol, bld.gluc.low.eff.poss.
   sev. ren./hepat.insuffic.in which case insul.is recomm., miconazole   potent. by other antidiab. agents/ß-block./ ketoconazole/ flu-  DIARAN MR 30, Ranbaxy [P/S]
   treatm., pregn., lactat.     conazole/ACE inhibit./H2 recept.antagon./ MAOI/sulphonamid./   Gliclazide.
   Side effects: Hypoglycaem.with poss.signs of adrenerg.counter-  clarithromyc./ NSAID’s & chloramphen., bld.gluc. lev.incr.by danazol/   Indications: Maturity onset diabet.mellit.(non-insul.depend./Type
   regulat., GI disturbs., skin reacts. incl.Stev.John.syndr.& TEN, drug   chlorpromaz./glucocortic./ salbutam./ terbutal./other ß-adrenerg.  2) where diet.managem. insuffic.
   rash with eosinophil. & system.sympts.(DRESS), bld.dyscras., incr.   agon./ ephedr./ pseudoephedr & common cold preps., expos.decr.  (S3) TABS, 41/21.2/0698
   hepat.enzym.lev., trans.vis.disturbs., class attribut.effs.of allerg.  by St John’s Wort, dysglycaem.risk with fluoroquinolones, act.of   714909-001: 30 mg, 30, R61,23
   vasculit./hyponatraem., liv. funct.impairm., hepatit.poss.lead.to   anticoag.(warfar.) potent.  Dosage: Adults: Init.30 mg once dly.with breakf. Dos.may vary from
   life-threat. liv.fail.                                     30-120 mg as sngl.dly.dos. Should dos.be forgot., do not incr.dos.the
   Warnings and special precautions: Assoc. incr.CV mortal.as   DIAMIN, AI Pharm Ltd [P/S]  next day. Dos.to be adjust.accord.to indiv.pt.metabol. respons. If fast.
   compar.to diet alone/diet & insulin., monit.concom.anticoags.&   Metformin HCl.  bld.gluc.lev.not decr.satisfact. incr. progress.to 60, 90 or 120 mg/day
   dos.adjustm. poss., reduc.dos.poss.necess.in mild to mod.ren. im-  Indications: Type II diab.mellit.when diet.fail. esp. if pt.overweight.,   by success. increm.at interv.of at least 1 mnth. Where bld.gluc.lev.
                                                                                   nd
   pairm., poor nutrit./irreg./miss.meals/condit. favour.hypoglycaem.,   alone as init.ther./in combinat. with a sulphonylurea or insulin.  has not decr.aft.15 days incr. poss.at the end of 2  wk.of treatm.
   hypoglycaem.risks tog.with sympts./treatm.& predispos.condits.to   (S3) TABS, A40/21.2/0464, 0465  Max.dly.dos: 120 mg.
   be explain., imbal.betw.physic.exerc.& carbohydr.intake, bld. gluc.  714186-001: 500 mg, 100, R46,86  Pt.stabilis.on gliclazide 80 mg:, replacem.may init.be based on:
   contr.poss.affect.by fev./trauma/infect.or surg. intervent.& insul.  714186-002: 500 mg, 500, R234,32  1 tab gliclazide 80 mg = 1 Diaran MR tab.
   admin.poss.necess., second. fail aris.from effic.poss.attenuat.over   714187-002: 850 mg, 60, R51,88  With transit.from anoth.sulfonylurea treatm., take into account the
   time due to dis progress/reduc.treatm.respons., consid.adeq. dos.ad-  714187-001: 850 mg, 300, R259,41  dos.& half-life of prev.oral hypoglycaem.agent. If chang.to anoth.
   just.& diet.compliance bef.second.fail. classific., monit.bld.gluc.with   Dosage: Admin.in div.dos.with meals.  sulfonylur. with prolong.half-life, therap.window of few days nec-
   concom. fluoroquinolones & St John’s Wort, shock/post. anaesth.,   Adults: Init.500 mg 3x/day. Incr./adjust dos.aft.10-15 days to 850   cess.to avoid subseq.hypoglycaem.risk. Recomm. to init.treatm.
   discont.in event of cholestat.jaund., consid. non-sulphonylur.alternat.  or 1 000 mg 2x/day.to max.3 g dly. Slow incr.may improve GI toler.   with Diaran MR tabs. 30 mg/ day & then incr.dos.in increm.accord.
   with G6PD defic., when tfd.from another oral hypoglycaem.consid.   Dos.may be reduc. when contr.obtain.  to indiv.metab.evaluat.
   dos. & half-life of prev.agent., ß-block.may mask sympathomimet.  Contraindications: Diabet.coma/ketoacidos. hist., imp.ren.funct.,   May be giv.in combinat.with alpha glucosidase inhibits. or insu-
   warn. signs of hypoglycaem.& inhib.norm.physiolog. respons., do   pancreatit., chron.liv.dis., hist.of/states assoc.with lact.acidos.   lin. Great.CV mortality risk in combin. ther.with biguanides than
   not admin.with heredit.galact.intol./Lapp lact.defic.or gluc.galact.   eg.shock/ pulm.insuffic., card.fail., recent MI, condits.assoc. with   gliclazide alone.
   malabsorpt.as lactose poss.affects. glycaem. control, safety in   hypoxem., hepat. insuff., ac.alcoh.intox., alcohol., safety in pregn.&   Contraindications: Sulfonylur.intol., Type 1 diab.mellit., ketoaci-
   pregn.& lactat.not est., hypoglycaem. can recur.even if init.meas.  lactat.not est., safety & effic.not est.in childr.  dos., sev.infect./trauma/ sev.condits.where hypoglycaem.contr.un-
   prove effect.theref.seek medic.treatm.  Side effects: GI disturbs., metall.taste, megaloblast. anaem.,   likely, safety in pregn.& lactat.not est.
   Drug interactions: Miconazole & phenylbutazone incr.hypo-  ketoacidos., ketonur., sev. cholestat.hepatit., hypersens.reacts.,   Side effects: Bld.dyscras., hypersens.reacts., GI disturbs., metall.
   glycaem.eff., avoid alcohol/meds cont. alcohol, bld.gluc.low.eff.  hypoglycaem., poss.Vit.B 12 malabsorpt.with longt. use, lact.acidos.  taste, cholestat.jaund., photosens., skin reacts.incl.Stev.-John.syndr./
   poss.potent.by other antidiab. agents/ß-block./ketoconazole/ flu-  Special precautions: Avoid alcoh./alcoh.-cont. meds., ther.assoc.  erythema multiforme/exfoliat.dermatit.
   conazole/ ACE inhibit./H2 recept.antagon./ MAOI/sulphonamid./  with incr.CV mort.risk, concom. ACE inhibits./warfar./cimetidine, el-  Special precautions: Avoid in ren./hepat. funct. impairm.esp.
   clarithromyc./NSAID’s & chloramphen., bld.gluc.lev.incr.by danazol/   derly, assess risk fact. assoc.with lact.acidos.& discont.ther./ treat   elderly/debilit./malnourish., adren. pituit.insuffic., caref.bld.gluc.
   chlorpromaz./glucocortic./salbutam./terbutal./ other ß-adrenerg.  as med.emerg.if susp., ren.funct.monit.bef. init. ther.& reg.thereaft.,   monit. essent., assoc.incr.CV mortal.as compar.to diet alone/ diet
   agon./ephedr./pseudoephedr & common cold preps., expos.decr.  discont.48 hrs.bef.elect. surg. with gen. aneasthes./clinic.investigat.  & insulin., hypoglycaem.risk with combin. ther.
   by St John’s Wort, dysglycaem.risk with fluoroquinolones, act.of   such as IV urograph./angiograph.& reinst.aft.48 hrs.& aft. ren.funct.  Drug interactions: Sulphonamid./salicylates/ phenylbutazone/
   anticoag. (warfar.)potent.   contr.regain., not advis.in condits. caus. dehydrat./ser.infect./trauma   ß-adrenocept.block.agents/ MAOI/ ketoconazole/miconazole/
                                or low cal. intake, bld.gluc.monit.with concom.sulphonylur., annual   chloramphen./ clofibrate/ halofenate/cyclophosphamide/ dicou-
   DIAMICRON MR, Servier [P/S]  Vit.B 12 lev.dur.longt.ther., stabilis.pts.in hosp. if concom.insulin ad-  marol/ cimetid.may potent hypoglycaem. act., hypoglycaem.act.
   Gliclazide.                  min., contin.diet with reg. distribut. of carbohydr.intake dur.day/en-  poss.reduc.with thiazide diurets./ corticoster./oestrog./adrenaline,
   Indications: Maturity onset diabet.mellit.where diet.managem./  ergy-restrict. diet in overweight pts., where ren.funct. may become   ß-blocks. may mask hypoglycaem.sympt.& inhib. norm. physiolog.
   lifestyle & exerc.alone insuffic.  imp., concom.glucocortic./beta-2-agonist/diurets.  hypoglycaem.respons.
   (S3) TABS, 35/21.2/0178      Drug interactions: Decr.bld.gluc.lev.with ACE inhibits., reduc.
   702923-001: 30 mg, 60, R135,21  ren.clear.with cimetidine, warfar. activ.dimin., poss.hypoglycaem.  DYNA GLICLAZIDE SR 30, Pharma Dynamics [P/S]
   Dosage: Adults: Init:30 mg once dly.with breakf. If fast.bld.gluc.  with sulphonylur.  Gliclazide.
   lev.not decr.satisfact.incr.dos. progress.to 60 mg,90 mg or 120 mg/  Indications: Type 2 diabet.mellit.where diet.& exerc.alone can-
   day with 1 mnth. interv.betw.increm.except where bld.gluc. has   DIAPHAGE, Cipla Medpro [P/S]  not contr.hyperglycaem.
                        nd
   not decr.aft. 15 days when an incr.poss.at end of 2  wk.of treatm.   Metformin HCl.  (S3) SR TABS, 42/21.2/0249
   Max.dly dos: 120 mg.         Indications: Type II diab.mellit.in adults & childr. over 12 yrs.&   716953-001: 30 mg, 60, R61,20
   (S3) TABS, 43/21.2/0957      adolesc.when diet.& excerc. alone fail. & esp.if pt.is overweight,   Dosage: Adults: Dly.dos.may vary from 30-120 mg. Dos.is determ.
   718245-001: 60 mg, 30, R127,80  as monother./ combinat. ther.with other oral antidiab.agents or   by desir.gluc.control achiev. with low.dos.suffic.to obt.desir.metabol.
   Adults: Dly.dos.30-120 mg/day as sngl.dly.dos. with breakf. Adjust.  insul.in adults & as monother./in combin.with insul. in adolesc.&   contr. Dos.to be adjust.accord.to indiv.pt. metabol. respons.
   accord.to indiv.metabol. respons. Init.30 mg once dly.with breakf.  childr.over 12 yrs.  Init.dos: 30 mg once dly.with breakf. Should dos.be forgot.do not
   If fast.bld.gluc.lev.not decr.satisfact.incr.dos. progress. to 60 mg,90   (S3) TABS, 44/21.2/0771, 0772, 0773  incr.dos. If fast. bld.gluc.lev. not decr.satisfact., dos.may be incr.pro-
   mg or 120 mg/day with 1 mnth. interv.betw.increm.except where   719784-001: 500 mg, 90, R39,50  gress.to 60, 90 or 120 mg/day by success.increm.with interv. of at
   bld.gluc. has not decr.aft.15 days when an incr.poss.at end of 2   nd  719785-001: 850 mg, 60, R46,41  least 1 mnth.betw.each increm. except where bld.gluc.lev.has not
                                                                                   nd
   wk.of treatm. Max.dly.dos: 120 mg.  719786-001: 1 000 mg, 60, R50,05  decr.aft. 15 days when an incr.poss.at the end of 2  wk.of treatm.
   Gliclazide replacem.ther: 80 mg gliclazide = ½ tab.Diamicron   Dosage: Admin.in div.dos.with meals. Poss. improv. G/I tol.with   Max.dly.dos: 120 mg.
   MR 60 mg.                    slow.dos.incr.                In pt.stabilis.on gliclazide 80 mg, replacem.may init.be based on:
   Other sulphonylur.replacem.ther: When tfd. consid. dos.& half-  Adults: Init. 500 mg 2-3x.dly or 1x 850 mg or 1x 1 000 mg tab 2xdly.  1 tab gliclazide 80 mg = 1 Dyna gliclazide SR tab.
   life of prev.oral hypoglycaem. If chang.from another oral sulphonylur.  with/aft.food. Dos.adjustm. based on bld.gluc.aft.10-15 days. Good   With transit.from anoth.sulfonylurea treatm., take into account the
   with prolong. half-life a therapeut.wind.of a few days poss. necess.   glycaem. contr. poss.aft.few days but full benef.poss. delay. for up   dos.& half-life of prev.oral hypoglycaem.agent. If chang.to anoth.
   to avoid addit.eff.& hypoglycaem. risk. Dur. changeover init.30 mg/  to 2 wks. Incr.dos.to max.2 550 mg/ day if contr.inadeq. Poss.dos.  sulfonylur. with prolong.half-life, therap.eut.window of few days
   day incr.increm. accord.to pts metabol.evolut.  reduc.once contr. has been achiev.   neccess.to avoid addit.eff.of 2 prod.& subseq. hypoglycaem.risk.
   Other oral antidiabet.combinat: Check control with bld.sugar   Childr.from 12 yrs & adolesc: Start.dos.usual. 500 mg or 850 mg   Recomm.to init. treatm. with 30 mg/day & then incr.dos.in increm.
   read.when combin.with alpha glucosid. inhibit./insul. Great.risk of   once dly.dur./aft.meals. Dos. adjustm. based on bld.gluc.aft.10-15   accord.to indiv.metabol.respons.
   CV mortal. when combin.with biguan.  days. Max. recomm.dos: 2 000 mg dly admin in 2-3 div.dos.  May be giv.in combinat.with alpha glucosidase inhibits.or insu-
   Contraindications: Other sulphonylurea/ sulphonam. hypersens.,   Contraindications: Diabet.ketoacidos./-pre-coma, ren.impairm.,   lin. Great.CV mortality risk in combin. ther.with biguanides than
   type 1 diab., diab. ketoacidos., diab.pre-coma& coma, childr., sev.   ac.condits.potent.alt.kidn. funct. eg.dehydrat.or low calor.intake/  gliclazide alone.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page326.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page322.html">322</a>&nbsp;&nbsp;&nbsp;<a href="page323.html">323</a>&nbsp;&nbsp;&nbsp;<a href="page324.html">324</a>&nbsp;&nbsp;&nbsp;<a href="page325.html">325</a>&nbsp;&nbsp;&nbsp;<a href="page326.html">326</a>&nbsp;&nbsp;&nbsp;<a href="page327.html">327</a>&nbsp;&nbsp;&nbsp;<a href="page328.html">328</a>&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>&nbsp;&nbsp;&nbsp;<a href="page330.html">330</a>&nbsp;&nbsp;&nbsp;<a href="page331.html">331</a>&nbsp;&nbsp;&nbsp;<a href="page332.html">332</a>
             </td>
             <td width="35%"><a href="page328.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page328.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
